Skip Navigation

Cardiovascular Research 1999 43(4):860-878; doi:10.1016/S0008-6363(99)00187-X
© 1999 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Jordan, J. E.
Right arrow Articles by Vinten-Johansen, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jordan, J. E.
Right arrow Articles by Vinten-Johansen, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1999, European Society of Cardiology

The role of neutrophils in myocardial ischemia–reperfusion injury

James E. Jordan, Zhi-Qing Zhao and Jakob Vinten-Johansen*

The Cardiothoracic Research Laboratory, Carlyle Fraser Heart Center of Crawford Long Hospital, 550 Peachtree Street N.E., Atlanta, GA 30365, USA

* Corresponding author. Tel.: +1-404-686-2511; fax: +1-404-686-4888 jvinten{at}emory.edu

Reperfusion of ischemic myocardium is necessary to salvage tissue from eventual death. However, reperfusion after even brief periods of ischemia is associated with pathologic changes that represent either an acceleration of processes initiated during ischemia per se, or new pathophysiological changes that were initiated after reperfusion. This ‘reperfusion injury’ shares many characteristics with inflammatory responses in the myocardium. Neutrophils feature prominently in this inflammatory component of postischemic injury. Ischemia–reperfusion prompts a release of oxygen free radicals, cytokines and other proinflammatory mediators that activate both the neutrophils and the coronary vascular endothelium. Activation of these cell types promotes the expression of adhesion molecules on both the neutrophils and endothelium, which recruits neutrophils to the surface of the endothelium and initiates a specific cascade of cell–cell interactions, leading first to adherence of neutrophils to the vascular endothelium, followed later by transendothelial migration and direct interaction with myocytes. This specific series of events is a prerequisite to the phenotypic expression of reperfusion injury, including endothelial dysfunction, microvascular collapse and blood flow defects, myocardial infarction and apoptosis. Pharmacologic therapy can target the various components in this critical series of events. Effective targets for these pharmacologic agents include: (a) inhibiting the release or accumulation of proinflammatory mediators, (b) altering neutrophil or endothelial cell activation and (c) attenuating adhesion molecule expression on endothelium, neutrophils and myocytes. Monoclonal antibodies to adhesion molecules (P-selectin, L-selectin, CD11, CD18), complement fragments and receptors attenuate neutrophil-mediated injury (vascular injury, infarction), but clinical application may encounter limitations due to antigen–antibody reactions with the peptides. Humanized antibodies and non-peptide agents, such as oligosaccharide analogs to sialyl Lewisx, may prove effective in this regard. Both nitric oxide and adenosine exhibit broad spectrum effects against neutrophil-mediated events and, therefore, can intervene at several critical points in the ischemic–reperfusion response, and may offer greater benefit than agents that interdict at a single point in the cascade. The understanding of the molecular processes regulating actions of neutrophils in ischemic–reperfusion injury may be applicable to other clinical situations, such as trauma, shock and organ or tissue (i.e. vascular conduits) transplantation.

KEYWORDS Neutrophils; Endothelium; Nitric oxide; Adenosine; Infarction; Reperfusion injury; Inflammation; Monoclonal antibodies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Exp PhysiolHome page
B. Metzler, B. Haubner, E. Conci, J. Voelkl, J. Jehle, M. Bauer, D. Wolf, O. Pachinger, and Q. Xu
Myocardial ischaemia-reperfusion injury in haematopoietic cell-restricted {beta}1 integrin knockout mice
Exp Physiol, July 1, 2008; 93(7): 825 - 833.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. Neumann, S. Sauerzweig, R. Ronicke, F. Gunzer, K. Dinkel, O. Ullrich, M. Gunzer, and K. G. Reymann
Microglia Cells Protect Neurons by Direct Engulfment of Invading Neutrophil Granulocytes: A New Mechanism of CNS Immune Privilege
J. Neurosci., June 4, 2008; 28(23): 5965 - 5975.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
N. Ojha, S. Roy, J. Radtke, O. Simonetti, S. Gnyawali, J. L. Zweier, P. Kuppusamy, and C. K. Sen
Characterization of the structural and functional changes in the myocardium following focal ischemia-reperfusion injury
Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2435 - H2443.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.